Key Insights

Highlights

Treatment Research

4 treatments under study, led by Bevacizumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06856837Phase 2Recruiting

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Showing all 1 trials

Research Network

Common Treatments

  • Bevacizumab1
  • Fruquintinib1
  • Tislelizumab1
  • Trifluridinetipiracil1

Active Sponsors

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1

Top Investigators

Related Conditions

  • Metastatic Colorectal Cancer1

Activity Timeline